According to our (Global Info Research) latest study, the global Intramuscular Injection of Pain Medication market size was valued at US$ 2212 million in 2025 and is forecast to a readjusted size of US$ 3274 million by 2032 with a CAGR of 6.1% during review period.
In 2025, the global production of intramuscular injection of pain medication reached approximately 768 million units, with an average global market price of around US$2.8 per unit. In the same year, the global total production capacity of intramuscular injection of pain medication reached 960 million units. The industry average gross profit margin of this product reached 47%.
Intramuscular analgesics are drugs and preparations administered via intramuscular injection to relieve moderate to severe pain or acute pain requiring rapid onset of action. After injection into muscle tissue, the drugs are absorbed into the systemic circulation through the rich local capillary network. Compared to some oral preparations, they typically have a faster onset of action, avoid gastrointestinal absorption instability, and are suitable for patients who cannot take oral medication. Based on their pharmacological mechanisms, intramuscular analgesics can include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, and some centrally acting drugs or compound preparations with analgesic effects. Specific varieties vary depending on national drug registration, clinical guidelines, and prescription management regulations. These products are mainly used for perioperative pain, traumatic pain, acute musculoskeletal pain, renal colic, and other clinical scenarios requiring short-term rapid analgesia. The selection and administration of these drugs are usually determined by healthcare professionals based on the degree of pain, the patient's underlying condition, and the risks associated with medication. Special attention must be paid to the safety risks associated with different categories of drugs, including gastrointestinal, renal, cardiovascular, respiratory depression, and dependence.
The upstream of the intramuscular injection analgesic drug industry chain mainly includes chemical raw materials, pharmaceutical excipients, water for injection, and pharmaceutical packaging materials. Among them, raw materials involve the corresponding analgesic active ingredients and their key intermediates, excipients include buffers, solubilizers, stabilizers, antioxidants, etc., and the packaging stage mainly uses pharmaceutical packaging products such as ampoules, vials, pre-filled syringes, rubber stoppers, and aluminum caps. The midstream consists of raw material manufacturers and injectable drug manufacturers. The core links cover raw material synthesis and purification, formulation development, aseptic preparation, filtration, filling, sterilization or aseptic production, quality testing, stability studies, and drug registration applications, which have high requirements for GMP management, aseptic production environment, and quality control system. The downstream is mainly used in hospitals, emergency centers, surgical centers, primary healthcare institutions, pain clinics, orthopedic departments, and other medical terminals, and is distributed by pharmaceutical commercial companies, professional drug distribution companies, and hospital pharmacies. Because some potent analgesics are strictly regulated or prescription drugs, their production, distribution, inventory, and clinical use are subject to rigorous supervision. Therefore, supply chain stability, product compliance, hospital access, centralized procurement, and coverage of clinical guidelines are crucial factors influencing a company's market competitiveness.
The overall market for intramuscular analgesics is expected to maintain relatively stable clinical demand in the future, primarily driven by increased global surgical volume, a growing number of trauma and emergency patients, an aging population, and improved standardized management of perioperative and acute pain. At the same time, industry development is not simply reliant on increased use of traditional potent analgesics, but is gradually evolving towards safer, more precise, and multimodal analgesia. Clinical practice increasingly emphasizes stratified medication based on pain intensity and patient risk, and reduces unnecessary opioid exposure through NSAIDs, local anesthetics, and other non-opioid analgesic regimens. Therefore, injectable analgesics with rapid onset of action, stable efficacy, lower risk of gastrointestinal or central nervous system adverse reactions, and high ease of administration are expected to have significant growth potential. Prefilled formulations, unit-dose packaging, and products suitable for day surgery and rapid analgesia in emergency situations are also likely to see wider adoption. However, this market is also affected by factors such as consistency evaluation of injectable drugs, price competition of generic drugs, centralized procurement, strict regulation of opioids, and substitution of oral, intravenous, transdermal and local administration methods. In the future, the focus of competition among companies will be more on product safety, differentiated indications, formulation technology, cost control and hospital terminal coverage.
Report Scope
This report is a detailed and comprehensive analysis for global Intramuscular Injection of Pain Medication market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Intramuscular Injection of Pain Medication market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Intramuscular Injection of Pain Medication market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Intramuscular Injection of Pain Medication market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Intramuscular Injection of Pain Medication market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Intramuscular Injection of Pain Medication
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Intramuscular Injection of Pain Medication market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Pfizer, Sanofi, Hengrui Medicine, Hikma Pharmaceuticals, Fresenius Kabi, Baxter International Inc., Maruishi Pharmaceutical Co., Ltd., Ketorolac Tromethamine Injection, Sun Pharmaceutical Industries Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Intramuscular Injection of Pain Medication market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Opioid Analgesics (Opioids)
Local Anesthetics
Others
Market segment by Analgesic Potency
Medication for Mild-to-Moderate Pain
Medication for Moderate-to-Severe Pain
Medication for Severe Pain
Market segment by Duration of Analgesia
<4 Hours
4–8 Hours
8 Hours
Market segment by Application
Hospitals (Emergency Care, Surgery, and Inpatient Pain Management)
Clinics (Outpatient Pain Treatment and Short-Term Procedures)
Others (Emergency Medical Services, Nursing Care, and Other Medical Settings)
Major players covered
Novartis
Pfizer
Sanofi
Hengrui Medicine
Hikma Pharmaceuticals
Fresenius Kabi
Baxter International Inc.
Maruishi Pharmaceutical Co., Ltd.
Ketorolac Tromethamine Injection
Sun Pharmaceutical Industries Ltd.
Humanwell Healthcare (Group) Co., Ltd.
Yangtze River Pharmaceutical Group
KRKA, d. d.
Medochemie Ltd.
Polpharma S.A.
Gland Pharma Limited
Sopharma AD
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Intramuscular Injection of Pain Medication product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Intramuscular Injection of Pain Medication, with price, sales quantity, revenue, and global market share of Intramuscular Injection of Pain Medication from 2021 to 2026.
Chapter 3, the Intramuscular Injection of Pain Medication competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Intramuscular Injection of Pain Medication breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Intramuscular Injection of Pain Medication market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Intramuscular Injection of Pain Medication.
Chapter 14 and 15, to describe Intramuscular Injection of Pain Medication sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Intramuscular Injection of Pain Medication. Industry analysis & Market Report on Intramuscular Injection of Pain Medication is a syndicated market report, published as Global Intramuscular Injection of Pain Medication Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Intramuscular Injection of Pain Medication market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.